Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.
Identifieur interne : 000606 ( PubMed/Corpus ); précédent : 000605; suivant : 000607Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.
Auteurs : Raymond A. Tetteh ; Edmund T. Nartey ; Margaret Lartey ; Aukje K. Mantel-Teeuwisse ; Hubert G M. Leufkens ; Barbara A. Yankey ; Alexander N O. DodooSource :
- Drug safety [ 1179-1942 ] ; 2016.
Abstract
Patients initiated on highly active antiretroviral therapy (HAART) generally remain on medication indefinitely. A modification in the HAART regimen may become necessary because of possible acute or chronic toxicities, concomitant clinical conditions, development of virological failure or the advent of adverse drug events. The study documents adverse drug events of HIV-positive Ghanaian patients with HAART modifications. It also investigates the association between documented adverse drug events and HAART modification using an unmatched case-control study design.
DOI: 10.1007/s40264-016-0460-7
PubMed: 27638659
Links to Exploration step
pubmed:27638659Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.</title><author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name><affiliation><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Mantel Teeuwisse, Aukje K" sort="Mantel Teeuwisse, Aukje K" uniqKey="Mantel Teeuwisse A" first="Aukje K" last="Mantel-Teeuwisse">Aukje K. Mantel-Teeuwisse</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name><affiliation><nlm:affiliation>School of Public Health, Georgia State University, Atlanta, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27638659</idno><idno type="pmid">27638659</idno><idno type="doi">10.1007/s40264-016-0460-7</idno><idno type="wicri:Area/PubMed/Corpus">000606</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000606</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.</title><author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name><affiliation><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Mantel Teeuwisse, Aukje K" sort="Mantel Teeuwisse, Aukje K" uniqKey="Mantel Teeuwisse A" first="Aukje K" last="Mantel-Teeuwisse">Aukje K. Mantel-Teeuwisse</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name><affiliation><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name><affiliation><nlm:affiliation>School of Public Health, Georgia State University, Atlanta, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name><affiliation><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Drug safety</title><idno type="eISSN">1179-1942</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients initiated on highly active antiretroviral therapy (HAART) generally remain on medication indefinitely. A modification in the HAART regimen may become necessary because of possible acute or chronic toxicities, concomitant clinical conditions, development of virological failure or the advent of adverse drug events. The study documents adverse drug events of HIV-positive Ghanaian patients with HAART modifications. It also investigates the association between documented adverse drug events and HAART modification using an unmatched case-control study design.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27638659</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>17</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.</ArticleTitle><Pagination><MedlinePgn>1139-1149</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients initiated on highly active antiretroviral therapy (HAART) generally remain on medication indefinitely. A modification in the HAART regimen may become necessary because of possible acute or chronic toxicities, concomitant clinical conditions, development of virological failure or the advent of adverse drug events. The study documents adverse drug events of HIV-positive Ghanaian patients with HAART modifications. It also investigates the association between documented adverse drug events and HAART modification using an unmatched case-control study design.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The study was conducted in the Fevers Unit of the Korle Bu Teaching Hospital and involved patients who attended the HIV Care Clinic between January 2004 and December 2009. Data from 298 modified therapy patients (cases) were compared with 298 continuing therapy patients (controls) who had been on treatment for at least 1 month before the end of study. Controls were sampled from the same database of a cohort of HIV-positive patients on HAART, at the time a case occurred, in terms of treatment initiation ±1 month. Data were obtained from patients' clinical folders and the HIV clinic database linked to the pharmacy database. The nature of the documented adverse drug events of the cases was described and the association between the documented adverse drug events and HAART modification was determined by logistic regression with reported odds ratios (ORs) and their 95 % confidence interval (CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 298 modified therapy patients sampled in this study, 52.7 % of them had at least one documented adverse drug event. The most documented adverse drug event was anaemia, recorded in 18.5 % of modified therapy patients, all of whom were on a zidovudine-based regimen. The presence of documented adverse drug events was significantly associated with HAART modification [adjusted OR = 2.71 (95 % CI 2.11-3.48), p < 0.001].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among HIV patients on HAART, adverse drug events play a major role in treatment modification. Occurrence of adverse drug events may be used as a predictor for possible therapy modification. We recommend the institution of active pharmacovigilance in HIV treatment programmes as it permits the proper identification and characterisation of drug-related adverse events. This can help develop approaches towards their management and also justify therapy modifications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tetteh</LastName><ForeName>Raymond A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Department, Korle Bu Teaching Hospital, Korle-Bu, Accra, Ghana. r_niiatetteh@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nartey</LastName><ForeName>Edmund T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Legon, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantel-Teeuwisse</LastName><ForeName>Aukje K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leufkens</LastName><ForeName>Hubert G M</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicines Evaluation Board, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankey</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>School of Public Health, Georgia State University, Atlanta, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodoo</LastName><ForeName>Alexander N O</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Assoc Physicians India. 2009 May;57:384-8</RefSource><PMID Version="1">19634284</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2010 Jan 11;170(1):57-65</RefSource><PMID Version="1">20065200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 Jan 15;34(2):260-6</RefSource><PMID Version="1">11740716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Med. 2003 Dec 1;115(8):632-41</RefSource><PMID Version="1">14656616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2007;12(5):753-60</RefSource><PMID Version="1">17713158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1988 Jul;69(3):299-304</RefSource><PMID Version="1">3261597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Jun 20;351(9119):1881-3</RefSource><PMID Version="1">9652687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Pharmacol Toxicol. 2014 Jun 23;15:32</RefSource><PMID Version="1">24957052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jul;21 Suppl 4:S89-95</RefSource><PMID Version="1">17620758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):53-8</RefSource><PMID Version="1">16340473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2008 Apr;61(4):933-8</RefSource><PMID Version="1">18281306</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2007 Nov;8(8):483-90</RefSource><PMID Version="1">17944680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2007 Oct 15;45(8):1093-101</RefSource><PMID Version="1">17879931</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jul;21 Suppl 4:S55-63</RefSource><PMID Version="1">17620754</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2001 Oct 20;358(9290):1322-7</RefSource><PMID Version="1">11684213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2011 Sep 17;11:244</RefSource><PMID Version="1">21923929</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Pharmacol Ther. 1989 Nov;46(5):494-500</RefSource><PMID Version="1">2582706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 May 31;22(9):1039-46</RefSource><PMID Version="1">18520347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):407-14</RefSource><PMID Version="1">14615659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2000 Jun;30 Suppl 2:S96-116</RefSource><PMID Version="1">10860894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2007 Mar;59(3):569-72</RefSource><PMID Version="1">17255141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 Jul 15;41(2):217-24</RefSource><PMID Version="1">15983918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2006;11(6):741-9</RefSource><PMID Version="1">17310818</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Apr 02;9(4):e93106</RefSource><PMID Version="1">24695108</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 1989 Mar;79(3):340-9</RefSource><PMID Version="1">2916724</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 Apr 16;12(6):F37-9</RefSource><PMID Version="1">9583592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1987 Jul 23;317(4):192-7</RefSource><PMID Version="1">3299090</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pan Afr Med J. 2014 May 07;18:25</RefSource><PMID Version="1">25368714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Braz J Med Biol Res. 2006 Apr;39(4):495-505</RefSource><PMID Version="1">16612473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 1991 Jul;32(1):17-21</RefSource><PMID Version="1">1909542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pan Afr Med J. 2012;11:39</RefSource><PMID Version="1">22593775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 1993 Dec 1;138(11):923-36</RefSource><PMID Version="1">8256780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):304-10</RefSource><PMID Version="1">17414931</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2004 Jan;26(1):92-7</RefSource><PMID Version="1">14996521</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Compliance with Ethical Standards Sources of funding No sources of funding were used to assist in the preparation of this study. Conflict of interest Raymond A. Tetteh, Edmund T. Nartey, Margaret Lartey, Aukje K. Mantel-Teeuwisse, Hubert G.M. Leufkens, Barbara A. Yankey and Alexander N.O. Dodoo have no conflicts of interest that are directly relevant to the content of this study. Ethical approval Ethical approval for the study was obtained from the Ethical and Protocol Review Committee of the University of Ghana Medical School (UGMS) [MS-Et/M.6-P.5.3/2009-10].</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27638659</ArticleId><ArticleId IdType="doi">10.1007/s40264-016-0460-7</ArticleId><ArticleId IdType="pii">10.1007/s40264-016-0460-7</ArticleId><ArticleId IdType="pmc">PMC5045837</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000606 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000606 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27638659
|texte= Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27638659" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |